Incyte and Syndax Announce New England Journal of Medicine …
网页3 天之前 · Incyte (Nasdaq:INCY) and Syndax Pharmaceuticals (Nasdaq:SNDX) today announced that results from the pivotal Phase 2 AGAVE-201 trial of Niktimvo™ (axatilimab-csfr), an anti-CSF-1R antibody, in ...
Incyte: Phase 2 Trial Results Of Niktimvo In Chronic Graft-Versus …
网页3 天之前 · Business News. Incyte (INCY) and Syndax Pharmaceuticals (SNDX) announced that results from the pivotal Phase 2 AGAVE-201 trial of Niktimvo (axatilimab-csfr), an anti-CSF-1R antibody, in adult and pediatric patients with recurrent/refractory active chronic graft-versus-host disease or GVHD who had received at least two prior lines of systemic ...
Incyte’s CDK2 Inhibitor INCB123667 Shows Promising Evidence of …
网页2024年8月26日 · Incyte Forward-looking Statements Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the presentation of data for Incyte’s CDK2 inhibitor (INCB123667), the potential this CDK2 inhibitor offers for patients, and expectations regarding ongoing and future clinical ...
Incyte Announces Promising New Data on Oncology Candidate at …
网页Incyte INCY announced new data from a phase I study on pipeline candidate INCB123667 in patients with advanced solid tumors. INCB123667 is a highly selective, potential first-in-class CDK2 inhibitor.
Incyte Presents New Late-Breaking Data from Phase 2 Study …
网页WILMINGTON, Del. -- (BUSINESS WIRE)--Mar. 10, 2024-- Incyte (Nasdaq:INCY) today announced results from a Phase 2 study evaluating the efficacy and safety of povorcitinib (INCB54707), an oral JAK1 inhibitor, in adult patients with prurigo nodularis (PN).
Incyte Announces FDA Approval of Zynyz™ (retifanlimab-dlwr) for …
网页2023年3月22日 · WILMINGTON, Del. -- (BUSINESS WIRE)--Mar. 22, 2023-- Incyte (Nasdaq:INCY) today announced that the U.S. Food and Drug Administration (FDA) has approved Zynyz ™ (retifanlimab-dlwr), a humanized monoclonal antibody targeting programmed death receptor-1 (PD-1), for the treatment of adults with metastatic or …
Incyte Announces New Data from Phase 2 Study Evaluating …
网页2024年3月10日 · INCY. Randomized Phase 2 study met the primary endpoint in patents with hidradenitis suppurativa (HS), reinforcing efficacy and safety profile of ruxolitinib cream. Results presented as a...
Incyte’s Hold Rating: Balancing Drug Pipeline Progress and Market ...
网页4 天之前 · Incyte (INCY) Company Description: Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development and commercialization of proprietary therapeutics.
Incyte - Biopharmaceutical Company | Solutions for Unmet …
网页Incyte is a global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of novel medicines..
Incyte Completes Acquisition of Escient Pharmaceuticals | Incyte
网页2024年5月30日 · Incyte Completes Acquisition of Escient Pharmaceuticals. Acquisition strengthens Incyte’s Inflammation and Autoimmunity (IAI) pipeline and reinforces commitment to bring innovative solutions to patients.